Ursodeoxycholic acid for the treatment of liver cirrhosis

Background : ursodeoxycholic acid (UCDA) has been recognized as the only pair of primary biliary cirrhosis (PBC) in the treatment of effective drugs. However, UCDA right from the early stages of PBC to extensive fibrosis and cirrhosis of the progress of treatment has not been clearly demonstrated out. This study was designed to evaluate the UDCA right PBC liver fibrosis treatment. Methods and Results : In 103 cases PBC patients, randomized, double-blind, placebo-controlled trial of UDCA therapy. Markov model using histologic analysis of early and late during the rate of progress. Early been identified as having portal and portal around the lesion, no extensive fibrosis, but the late emergence of a large number identified as segregation, bridge fibrosis or cirrhosis. A total of 162 pairs of liver biopsy specimens were studied. The model accurately describes the observed data. UDCA treatment of early stage disease can to extensive fibrosis or cirrhosis decreased 5 times (UDCA therapy for a year 7%, and placebo in each of the 34%, P <0.002),>